T. Rowe Price Associates
OMIC

T. Rowe Price Associates’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

T. Rowe Price Associates’s Portfolio OMIC Stock Details OMIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-522
Closed -$60K – 3054
2022
Q2 		$60K Buy
522
+27
+5% +$3.17K ﹤0.01% 2837
2022
Q1 		$94K Buy
495
+112
+29% +$25.9K ﹤0.01% 2858
2021
Q4 		$133K Buy
+383
New +$148K ﹤0.01% 2830

Other funds holding OMIC

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Associates's OMIC Position: Q3 2022 in Review

T. Rowe Price Associates sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q3 2022, closing a stake of 522 shares — an estimated $60K sold.

T. Rowe Price Associates first reported a position in OMIC in Q4 2021 and held it in 3 quarters. The position peaked at $133K in Q4 2021. 74 funds tracked by Wall St. Rank hold OMIC as of Q3 2022.

  • T. Rowe Price Associates reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 522 Singular Genomics Systems, Inc. Common Stock shares in Q3 2022, an estimated $60K.
  • T. Rowe Price Associates first reported a position in Singular Genomics Systems, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • T. Rowe Price Associates's Singular Genomics Systems, Inc. Common Stock position peaked at $133K in Q4 2021.
  • 74 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q3 2022.

Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.